Parameter |
Variables |
Numbers |
% |
Nonsevere dengue |
Severe dengue |
Stats |
Age |
<3 yrs |
9 |
8.41% |
8 |
1 |
Mean age |
4–7 yrs |
27 |
25.33% |
21 |
6 |
||
8–11 yrs |
30 |
28.03% |
22 |
8 |
||
>11 yrs |
41 |
38.31% |
30 |
11 |
||
Sex |
Male |
61 |
57% |
45 |
16 |
|
Female |
46 |
43% |
36 |
10 |
|
|
Duration of hospitalization |
0–3 days |
12 |
11.21% |
10 |
2 |
Mean duration |
4–6 days |
69 |
64.49% |
56 |
13 |
||
>6 days |
26 |
24.30% |
15 |
11 |
||
Classification |
Undifferentiated fever |
21 |
19.63% |
|
|
|
DF (with and without warning signs) |
60 |
56.07% |
|
|
|
|
Severe dengue fever (DHF& DSS) |
26 |
24.30% |
|
|
|
Investigations |
Variations |
Nonsevere dengue (n=81) |
Severe dengue (n=26) |
Total (n=107) |
value |
TLC |
Leucopenia (<4000
cells/mm3) |
39 (48.14%) |
7 (26.92%) |
46 (42.99%) |
|
Leucocytosis (>11000 cells/mm3) |
3 (3.70%) |
2 (7.69%) |
5 (4.67%) |
|
|
Normal TLC (4000–11000/mm3) |
39 (48.14%) |
17 (65.38%) |
56 (52.33%) |
|
|
Liver enzymes |
Rise in SGPT (>40
IU/L) |
19 (23.45%) |
9 (34.61%) |
28 (26.16%) |
|
Rise in SGOT (>40 IU/L) |
21 (25.92%) |
9 (34.61%) |
30 (28.03%) |
|
|
TPC |
< 50000 |
6 (7.40%) |
18 (69.23%) |
24 (22.42%) |
|
50000-100000 |
26 (32.09%) |
6 (23.07%) |
32 (29.90%) |
|
|
>100000 |
12 (14.81%) |
2 (7.69%) |
14 (13.08%) |
|
|
Hematocrit |
>36.3% |
43 (53.08%) |
12 (46.15%) |
55 (51.40%) |
|
<36.3% |
38 (46.91%) |
14 (53.85%) |
52 (48.60%) |
|
|
Chest X-ray |
Pleural effusion |
4 (4.93%) |
6 (23.07%) |
10 (9.34%) |
0.0037 |
Right sided effusion |
2 (2.46%) |
4 (15.38%) |
6 (5.60%) |
0.4179 |
|
Left sided effusion |
2 (2.46%) |
2 (7.69%) |
4 (3.73%) |
|
|
USG of abdomen |
Hepatomegaly |
21 (25.92%) |
7 (26.92%) |
28 (23.16%) |
|
Ascites |
3 (3.70%) |
5 (19.23%) |
8 (7.47%) |
|
|
Gall bladder wall edema |
0 |
3 (11.53%) |
3
(2.80%) |
|
|
Dengue serology |
NS1 |
43 (40.18%) |
8 (7.47%) |
51 (47.66%) |
|
IgM |
48 (44.85%) |
22 (20.56%) |
70 (65.42%) |
|
|
IgG |
13 (12.14%) |
22 (20.56%) |
35 (32.71%) |
|
Management |
Nonsevere dengue(n=81) |
Severe dengue(n=26) |
Total (n=107) |
Antipyretics |
81 |
26 |
107 |
Intravenous fluids |
30 (37.04%) |
26 (100%) |
56 (52.34%) |
Platelet transfusion |
10 (12.35%) |
8 (30.77%) |
18 (16.82%) |
Blood transfusion |
0 |
4 (15.38%) |
4 (3.74%) |
Dopamine |
0 |
3 (11.54%) |
3 (2.80%) |